Austedo (deutetrabenazine) and Ingrezza (valbenazine) are two prescription medications specifically approved for treating movement disorders
Austedo vs. Ingrezza: Understanding the Differences for Movement Disorders
Austedo (deutetrabenazine) and Ingrezza (valbenazine) are two prescription medications specifically approved for treating movement disorders, primarily tardive dyskinesia. While both medicines work on similar pathways in the brain, they have distinct indications and characteristics that healthcare providers consider when determining the most appropriate treatment for a patient. Understanding these differences is crucial for patients and caregivers seeking information about their options.
What is Austedo (Deutetrabenazine)?
Austedo is a medication approved by the U.S. Food and Drug Administration (FDA) for two main conditions:
- Tardive Dyskinesia (TD) in adults.
- Chorea associated with Huntington's disease (HD).
It belongs to a class of drugs known as VMAT2 (vesicular monoamine transporter 2) inhibitors. Austedo works by regulating the levels of certain neurotransmitters, particularly dopamine, in the brain. By inhibiting VMAT2, it helps to reduce the excessive dopaminergic activity believed to contribute to involuntary movements seen in TD and HD chorea.
Key Characteristics of Austedo
- Indications: Tardive dyskinesia and chorea associated with Huntington's disease.
- Mechanism of Action: Reversible VMAT2 inhibitor, reducing dopamine release.
- Chemical Structure: A deuterated form of tetrabenazine, designed to have a longer half-life and potentially a more stable pharmacokinetic profile compared to its predecessor.
- Dosage: Typically started at a low dose and gradually increased by a healthcare provider based on patient response and tolerability.
What is Ingrezza (Valbenazine)?
Ingrezza is another FDA-approved VMAT2 inhibitor, but its primary indication is more specific:
- Tardive Dyskinesia (TD) in adults.
Similar to Austedo, Ingrezza functions by selectively inhibiting the VMAT2 transporter, leading to a reduction in the release of dopamine from nerve terminals. This targeted action helps to control the involuntary, repetitive movements characteristic of tardive dyskinesia.
Key Characteristics of Ingrezza
- Indications: Tardive dyskinesia only.
- Mechanism of Action: Selective, reversible VMAT2 inhibitor, reducing dopamine release.
- Chemical Structure: A prodrug that is metabolized to an active form, which then inhibits VMAT2.
- Dosage: Often starts with a specific dose, which may be adjusted by a healthcare provider.
Austedo vs. Ingrezza: Key Differences
While both medications are effective VMAT2 inhibitors for tardive dyskinesia, there are several distinguishing factors:
Approved Indications
- Austedo: Approved for both tardive dyskinesia and chorea associated with Huntington's disease.
- Ingrezza: Approved exclusively for tardive dyskinesia.
This difference in indications means that if a patient requires treatment for chorea related to Huntington's disease, Austedo would be the specific choice among these two medications.
Metabolism and Chemical Structure
- Austedo: Deutetrabenazine is a deuterated form of tetrabenazine. Deuteration modifies the drug's metabolism, leading to a longer half-life and potentially less frequent dosing compared to non-deuterated forms.
- Ingrezza: Valbenazine is a prodrug that is metabolized into an active form (alpha-dihydrotetrabenazine). Its metabolism and excretion profile also contribute to its clinical effectiveness.
These chemical and metabolic differences can influence aspects like dosing frequency, potential drug interactions, and the overall pharmacokinetic profile within a patient.
Dosage Regimen
While both drugs typically involve oral administration and titration, the specific dosing schedules and available strengths may differ. Healthcare providers carefully follow prescribing guidelines for each medication to optimize treatment while managing potential side effects.
Potential Side Effects Profile
As VMAT2 inhibitors, both medications share some common potential side effects, such as somnolence (drowsiness) and QT prolongation. However, the frequency and specific types of other side effects can vary. For instance, Austedo has specific warnings related to depression and suicidality due to its chemical lineage from tetrabenazine, which has similar warnings. Ingrezza also carries warnings regarding somnolence and QT prolongation, among others.
Similarities Between Austedo and Ingrezza
Despite their differences, Austedo and Ingrezza share fundamental similarities:
- Mechanism of Action: Both are VMAT2 inhibitors, working to reduce excessive dopamine signaling in the brain that contributes to involuntary movements.
- Primary Use: Both are highly effective and widely used for the treatment of tardive dyskinesia in adults.
- Oral Administration: Both medications are taken orally.
- Medical Supervision: Both require careful medical supervision, including dose titration and monitoring for side effects, due to their impact on neurotransmitter systems.
Choosing Between Austedo and Ingrezza
The decision to prescribe Austedo or Ingrezza is a complex medical one that must be made by a qualified healthcare professional. Factors considered typically include:
- The specific diagnosis (tardive dyskinesia only, or chorea associated with Huntington's disease).
- The patient's overall health and medical history.
- Other medications the patient is currently taking, to assess potential drug interactions.
- Individual tolerability and response to treatment.
- Potential side effect profiles and contraindications.
Patients should always discuss all their symptoms, medical conditions, and current medications with their doctor to ensure the most appropriate and safe treatment plan is selected.
Conclusion
Austedo and Ingrezza represent significant advancements in the treatment of movement disorders, particularly tardive dyskinesia. While both are VMAT2 inhibitors, Austedo's approved indication for Huntington's disease chorea sets it apart from Ingrezza, which is specifically for tardive dyskinesia. The choice between these medications involves a detailed assessment by a healthcare provider, considering the patient's unique clinical picture and treatment goals. For anyone experiencing involuntary movements, seeking professional medical advice is the essential first step to accurate diagnosis and effective management.